Literature DB >> 12089141

Detoxification of cholera toxin without removal of its immunoadjuvanticity by the addition of (STa-related) peptides to the catalytic subunit. A potential new strategy to generate immunostimulants for vaccination.

Joaquín Sánchez1, Gun Wallerström, Margareta Fredriksson, Jonas Angström, Jan Holmgren.   

Abstract

Peptides related to the heat-stable enterotoxin STa were fused to the N terminus of the A-subunit of cholera toxin (CTA) to explore whether peptide additions could help generate detoxified cholera toxin (CT) derivatives. Proteins carrying APRPGP (6-CTA), ASRCAELCCNPACPAP (16-CTA), or ANSSNYCCELCCNPACTGCYPGP (23-CTA) were genetically constructed. Using a two-plasmid system these derivatives were co-expressed in Vibrio cholerae with cholera toxin B-subunit (CTB) to allow formation and secretion of holotoxin-like molecules (engineered CT, eCTs). Purified eCTs maintained all normal CT properties yet they were more than 10-fold (eCT-6), 100-fold (eCT-16), or 1000-fold (eCT-23) less enterotoxic than wild-type CT. The inverse correlation between enterotoxicity and peptide length indicated sterical interference with the ADP-ribosylating active site in CTA. This interpretation agreed with greater than 1000-fold reductions in cAMP induction, with reductions, albeit not proportional, in in vitro agmatine ADP-ribosylation, and was supported by molecular simulations. Intranasal immunization of mice demonstrated that eCTs retained their inherent immunogenicity and ability to potentiate immune responses to a co-administered heterologous protein antigen, although in variable degrees. Therefore, the addition of STa-related peptides to CTA reduced the toxicity of CT while partly preserving its natural immunoadjuvanticity. These results suggest peptide extensions to CTA are a useful alternative to site-directed mutagenesis to detoxify CT. The simplicity of the procedure, combined with efficient expression and assembly of derivatives, suggests this approach could allow for large scale production of detoxified, yet immunologically active CT molecules.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12089141     DOI: 10.1074/jbc.M112337200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  12 in total

1.  Purification and characterization of Yersinia enterocolitica and Yersinia pestis LcrV-cholera toxin A(2)/B chimeras.

Authors:  Juliette K Tinker; Chadwick T Davis; Britni M Arlian
Journal:  Protein Expr Purif       Date:  2010-05-11       Impact factor: 1.650

Review 2.  Mechanisms of Cholera Toxin in the Modulation of TH17 Responses.

Authors:  Hsing-Chuan Tsai; Reen Wu
Journal:  Crit Rev Immunol       Date:  2015       Impact factor: 2.214

Review 3.  Mucosal vaccine delivery: Current state and a pediatric perspective.

Authors:  Akhilesh Kumar Shakya; Mohammed Y E Chowdhury; Wenqian Tao; Harvinder Singh Gill
Journal:  J Control Release       Date:  2016-02-06       Impact factor: 9.776

4.  Induction and recall of immune memory by mucosal immunization with a non-toxic recombinant enterotoxin-based chimeric protein.

Authors:  Christine M Gockel; Michael W Russell
Journal:  Immunology       Date:  2005-12       Impact factor: 7.397

Review 5.  Cholera toxin - a foe & a friend.

Authors:  Joaquin Sanchez; Jan Holmgren
Journal:  Indian J Med Res       Date:  2011-02       Impact factor: 2.375

6.  Characterization of fluorescent chimeras of cholera toxin and Escherichia coli heat-labile enterotoxins produced by use of the twin arginine translocation system.

Authors:  Juliette K Tinker; Jarrod L Erbe; Randall K Holmes
Journal:  Infect Immun       Date:  2005-06       Impact factor: 3.441

Review 7.  Cholera toxin: a paradigm of a multifunctional protein.

Authors:  Kaushik Bharati; Nirmal K Ganguly
Journal:  Indian J Med Res       Date:  2011-02       Impact factor: 2.375

8.  A binding motif for Hsp90 in the A chains of ADP-ribosylating toxins that move from the endoplasmic reticulum to the cytosol.

Authors:  Alisha Kellner; Michael Taylor; Tuhina Banerjee; Christopher B T Britt; Ken Teter
Journal:  Cell Microbiol       Date:  2019-07-05       Impact factor: 4.115

9.  Construction and evaluation of V. cholerae O139 mutant, VCUSM21P, as a safe live attenuated cholera vaccine.

Authors:  Chandrika Murugaiah; Nik Zuraina Nik Mohd Noor; Shyamoli Mustafa; Ravichandran Manickam; Lalitha Pattabhiraman
Journal:  PLoS One       Date:  2014-02-05       Impact factor: 3.240

10.  Mucosal vaccine adjuvants update.

Authors:  Joon Haeng Rhee; Shee Eun Lee; Soo Young Kim
Journal:  Clin Exp Vaccine Res       Date:  2012-07-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.